摘要
目的 检测各型冠心病患者外周血炎症标志物C反应蛋白 (CRP)、丙二醛 (MDA)与vonWillebrand因子(vWF)以及辛伐他汀对冠心病患者调脂以外的作用。方法 血脂正常的冠心病患者 14 0例 ,其中稳定性心绞痛(SAP) 4 0例 ,不稳定性心绞痛 (UAP) 5 0例 ,急性心肌梗死 (AMI) 5 0例。每种病例随机分为两组 ,一组为辛伐他汀治疗组 ,一组为常规治疗组 ;正常对照组 2 0例。分别于入院时及治疗后 1周两次检测上述标志物。结果 三组病例的CRP、MDA、vWF均显著高于对照组 (P <0 .0 0 1) ,AMI组显著高于SAP及UAP组 (P <0 .0 0 1) ;辛伐他汀治疗组可以使三种指标显著下降 (P <0 .0 5 )。结论 炎症反应、氧化应激及血管内皮损伤在冠心病的发病机制及进展中起重要作用 ,辛伐他汀可以抑制炎症反应、氧化应激 ,修复内皮从而稳定病变进展。
Objective To investigate the serum level of C-reactive protein(CRP)?MDA and von Willebrand factor(vWF) in patients with coronary artery disease(CAD),and their changes after being interventioned by simvastatin. Methods The concentration of CRP,MDA and vWF were measured in 140 patients with CAD and 20 healthy persons, 40 patients with stable angina pectoris(SAP), 50 unstable angina pectoris(UAP) and 50 acute myocardial infarction(AMI). Every kind of CAD was divided into two groups in which one was interventioned by simvastatin and the other not. After being interventioned for 7 days, the concentration of those markers was measured again. Results The average concentration of CRP,MDA and vWF was significantly higher than that of control group( P <0.001), and with CAD progressing, the concentration increased( P <0.001) . The higher serum level of CRP,MDA and vWF significantly decreased in simvastatin group( P <0.05). Conclusion Inflammatory markers elevated in patients with CAD, and early intervention with simvastatin could inhibit inflammatory reaction.
出处
《医师进修杂志》
北大核心
2003年第11期27-29,共3页
Journal of Postgraduates of Medicine
